Jeremy Bender Day One Biopharmaceuticals, Inc. (DAWN) insider trading activity

Jeremy Bender is CHIEF EXECUTIVE OFFICER of Day One Biopharmaceuticals, Inc.. Currently has a direct ownership of 177,165 shares of DAWN, which is worth approximately $1.56 Million. The most recent transaction as insider was on Nov 17, 2025, when has been sold 15,894 shares (Common Stock) at a price of $8.91 per share, resulting in proceeds of $141,615. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 177K

9.79% 3M change

63.47% 12M change

Total Value Held $1.56 Million

Jeremy Bender Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 17 2025	SELL Open market or private sale	$141,615 $8.91 p/Share	15,894 Reduced 8.23%	177,165 Common Stock
Nov 15 2025	BUY Exercise of conversion of derivative security	-	31,694 Added 14.1%	193,059 Common Stock
Aug 18 2025	SELL Open market or private sale	$108,712 $6.77 p/Share	16,058 Reduced 9.05%	161,365 Common Stock
Aug 15 2025	BUY Exercise of conversion of derivative security	-	31,686 Added 15.15%	177,423 Common Stock
May 16 2025	SELL Open market or private sale	$87,414 $6.26 p/Share	13,964 Reduced 8.74%	145,737 Common Stock
May 15 2025	BUY Exercise of conversion of derivative security	-	31,686 Added 16.56%	159,701 Common Stock
Feb 18 2025	SELL Open market or private sale	$144,094 $11.96 p/Share	12,048 Reduced 8.6%	128,015 Common Stock

Feb 15 2025	BUY Exercise of conversion of derivative security	-	31,686 Added 18.45%	140,063 Common Stock
Nov 18 2024	SELL Open market or private sale	$139,418 $13.21 p/Share	10,554 Reduced 8.87%	108,377 Common Stock
Nov 15 2024	BUY Exercise of conversion of derivative security	-	19,999 Added 14.4%	118,931 Common Stock
Aug 16 2024	SELL Open market or private sale	$149,534 $14.0 p/Share	10,681 Reduced 9.74%	98,932 Common Stock
Aug 15 2024	BUY Exercise of conversion of derivative security	-	19,999 Added 15.43%	109,613 Common Stock
May 16 2024	SELL Open market or private sale	$126,597 $16.08 p/Share	7,873 Reduced 1.19%	654,728 Common Stock
May 15 2024	BUY Exercise of conversion of derivative security	-	19,999 Added 2.93%	662,601 Common Stock
May 03 2024	SELL Open market or private sale	$163,398 $17.85 p/Share	9,154 Reduced 1.4%	642,602 Common Stock
May 02 2024	SELL Open market or private sale	$107 $17.94 p/Share	6 Reduced 0.0%	651,756 Common Stock
May 01 2024	SELL Open market or private sale	$1,252,511 $17.88 p/Share	70,051 Reduced 9.7%	651,762 Common Stock
Feb 16 2024	SELL Open market or private sale	$116,128 $15.25 p/Share	7,615 Reduced 1.04%	721,813 Common Stock
Feb 15 2024	BUY Exercise of conversion of derivative security	-	19,999 Added 2.67%	729,428 Common Stock
Nov 16 2023	SELL Open market or private sale	$36,320 $11.69 p/Share	3,107 Reduced 0.44%	709,429 Common Stock
Nov 15 2023	BUY Exercise of conversion of derivative security	-	8,312 Added 1.15%	712,536 Common Stock
Aug 17 2023	SELL Open market or private sale	$41,524 $13.86 p/Share	2,996 Reduced 0.42%	704,224 Common Stock
Aug 15 2023	BUY Exercise of conversion of derivative security	-	8,312 Added 1.16%	707,220 Common Stock
Jul 01 2023	SELL Other acquisition or disposition	-	240,288 Reduced 20.37%	939,196 Common Stock
Jul 01 2023	SELL Bona fide gift	-	240,288 Reduced 25.58%	698,908 Common Stock

Also insider at

FUSN

Fusion Pharmaceuticals Inc. Healthcare

MREO

Mereo Biopharma Group plc Healthcare

Jeremy Bender

CHIEF EXECUTIVE OFFICER

South San Francisco, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells DAWN shares.

Notify only if

Value

Insider Trading

Get notified when an Day One Biopharmaceuticals, Inc. insider buys or sells DAWN shares.

Notify only if

Operation

Value

Type

News

Receive news related to Day One Biopharmaceuticals, Inc.

Track Activities on DAWN

Account